
Retatrutide
Retatrutide
Triple-Agonist Fat Loss Peptide • GLP-1 + GIP + Glucagon Activation • Metabolic Reset • Appetite Control


Benefits of Retatrutide
Superior Appetite Control
Reduced cravings
Smaller portion sizes
Increased fullness
Less emotional eating
Rapid & Significant Fat Loss
Most powerful weight-loss peptide available
Reduces visceral fat
Leaner waist and midsection
Helps break plateaus
Improved Metabolic Health
Better glucose control
Lower HbA1c
Reduced insulin resistance
Stabilised blood sugar
Increased Energy & Fat Oxidation
Faster metabolism
More natural daily energy
Improves endurance & workout recovery
Protective Benefits
Supports liver health (reduced fatty liver)
Lowers cardiovascular and metabolic risk markers
Reduces inflammation
How Retatrutide Works (Mechanisms of Action)
1. GLP-1 Activation → Appetite Reduction
Reduces hunger centres in the brain
Increases satiety
Slows gastric emptying
Stabilises blood sugar
This results in naturally reduced calorie intake without cravings.
2. GIP Activation → Improves Metabolism
GIP improves insulin sensitivity, stabilises glucose, and supports:
better energy partitioning
reduced fat storage
improved post-meal glucose control
3. Glucagon Activation → Fat Burning
Unlike GLP-1 and GIP alone, glucagon:
increases basal metabolic rate
accelerates fat oxidation
helps maintain lean mass during weight loss
4. Triple Pathway Synergy
The combined activation of all three receptors creates:
faster fat loss
more consistent appetite control
less plateauing
improved metabolic flexibility
stronger improvements in HbA1c
5. Enhances Mitochondrial Activity
Retatrutide increases metabolic output at the cellular level, supporting:
higher energy levels
improved exercise tolerance
greater fat-burning efficiency
What Is Retatrutide?
Retatrutide is one of the most advanced fat-loss medications ever developed — a triple hormone agonist that activates:
GLP-1 receptors → appetite suppression, delayed gastric emptying, improved insulin response
GIP receptors → enhanced glucose control & metabolic flexibility
Glucagon receptors → increased energy expenditure and fat oxidation
This makes Retatrutide significantly more powerful than semaglutide or tirzepatide.
In multiple clinical trials, Retatrutide showed the highest weight-loss outcomes of any obesity medication ever tested, with participants losing up to 24% of total body weight.




Dosage, Injection Volume & Cycling
Concentration:
60 mg / 10 ml (6 mg/ml)
Dose:
Starting Dose (Weeks 1–4):
2 mg weekly = 0.33 ml SC
Titration (Weeks 5–8):
4 mg weekly = 0.66 ml SC
Target Dose (Weeks 9–12+):
6 mg weekly = 1 ml SC
Injection Volume:
2 mg → 0.33 ml SC
4 mg → 0.66 ml SC
6 mg → 1 ml SC
Synergy Stacks
Metabolic Health Stack
Retatrutide + Glutathione
Protects liver, reduces inflammation,
improves insulin sensitivity.
Max Fat Loss Stack
Retatrutide + CJC-1295 DAC + Ipamorelin
GH support + metabolic acceleration.
Performance & Lean Mass Protection
Retatrutide + Epithalon
Telomere & sleep support → improves recovery.
All treatments include a brief consultation and are supervised by qualified clinicians.
Who Is Retatrutide Ideal For?
Individuals Struggling With Weight
Slow metabolism
Hormonal weight gain
History of yo-yo dieting
Metabolic Syndrome or Insulin Resistance
High insulin
Pre-diabetes
Fatty liver
PCOS-related weight issues
Gym-Goers Trying to Lean Out
Belly fat
Stubborn fat around hips/love handles
Bulking rebound weight
Cycle:
12–24 weeks continuous
(longer cycles produce the best results)
Injection Sites:
Subcutaneous (SC) or Intramuscular (IM)
Rotate injection sites
Can inject near injury site
Best Injection Time:
Morning of a low-activity day
With electrolytes / hydration support
Aesthetic Fat-Loss Stack
Retatrutide + NAD+ IM/SC
Supports energy, reduces inflammation, accelerates fat
oxidation.
Safety & Side Effects
Most common:
Nausea
Fullness / reduced appetite
Mild GI discomfort
Heartburn
Low energy during first few weeks
Less common:
Constipation or diarrhoea
Temporary increased sensitivity in nerves
Headaches
Side effects reduce significantly after titration.
Anyone Needing Strong Appetite Control
Post-Pregnancy or Menopause Weight Gain
Retatrutide — Scientific Research & Clinical Studies
Phase 2 obesity trial (NEJM) – 48-week, placebo-controlled trial in adults with obesity; retatrutide produced up to ~24% body-weight reduction. New England Journal of Medicine+1
https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
https://pubmed.ncbi.nlm.nih.gov/37366315/
Substudy: liver fat & metabolic disease (Nat Med) – In patients with MASLD, retatrutide markedly reduced liver fat and improved metabolic markers. Nature
https://www.nature.com/articles/s41591-024-03018-2
Industry clinical summary – Eli Lilly’s publication summarising trial outcomes and weight-loss efficacy. Lilly Investor Relations
https://investor.lilly.com/news-releases/news-release-details/lillys-phase-2-retatrutide-results-published-new-england-journal
(Important: still investigational; not yet broadly approved.)
Clinical Disclaimer
This information is derived from clinical research, endocrine physiology, and metabolic science. Retatrutide at The NAD Clinic is used under a research-based wellness protocol and is not intended to diagnose, treat, or cure disease.



